Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

AbbVie likely to retain key position in axial spondyloarthritis digital marketing space in Japan, says GlobalData

Historically, anti-tumor necrosis factor (TNF) drugs were the key biologic therapies available in Japan for axial spondyloarthritis (axSpA) treatment. However, the overall competition with the new class of marketed biologics such as anti-IL-17 therapies and the marketed biosimilars is expected to impact the sales of leading drugs — AbbVie’s Humira and Janssen’s/Mitsubishi Tanabe’s Remicade. Against […]
Read more

Growing importance of AI in pharmaceutical industry is mirrored by steady rise in AI-related job postings, says GlobalData

There has been a strong increase of vacancies in artificial intelligence (AI) related jobs in the pharmaceutical sector this year, despite the impact of COVID-19, says GlobalData. According to the leading data and analytics company’s Jobs Analytics database, the number of AI-related job announcements tripled from over 1000 in Q3 2019 to more than 3,000 […]
Read more

Plaque psoriasis population to reach over 16.8 million by 2030 in the 7MM influenced by obesity, type 2 diabetes and smoking, says GlobalData

The number of individuals with diagnosed plaque psoriasis in the seven major markets (7MM*) is projected to increase from around 15,720,000 in 2020 to over 16,850,000 in 2030, at an annual growth rate (AGR) of 0.72% according to GlobalData, a leading data and analytics company. These increases are likely to subsequently increase the size of […]
Read more

Neurology digital therapeutics market in Japan nascent, but several opportunities exist, says GlobalData

Digital therapeutics (DTx) uses digital technology to remotely prevent, treat, or manage a wide range of conditions through data-driven interventions. The digital therapeutics market for neurological diseases in Japan is nascent but several opportunities exist, says GlobalData, a leading data and analytics company. Shionogi & Co Ltd, a partner of Akili Interactive (Akili), a prescription […]
Read more

AbbVie’s Qulipta set to become blockbuster in the migraine market

AbbVie has recently announced that Qulipta (atogepant) has received FDA approval for the preventive treatment of episodic migraine in adults. Qulipta is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of migraine. The market for oral prophylactic treatments to reduce the number of migraine days […]
Read more

Pharma industry needs to outsource manufacturing for COVID-19 vaccine boosters and children’s doses, says GlobalData

The pharmaceutical industry will need to outsource even more pharmaceutical manufacturing to keep up the pace with the expected developments of the COVID-19 vaccines and drugs, says GlobalData, a leading data and analytics company. GlobalData’s report, ‘COVID-19: Contract Pharmaceutical Development and Manufacturing Relationships’, reveals that the coming changes, like the approval of COVID-19 vaccines in […]
Read more

Boxed warnings and restrictive labelling for Incyte’s atopic dermatitis topical Opzelura sets precedent for pipeline topical JAK inhibitors, says GlobalData

While GlobalData expects the approval of Opzelura (ruxolitinib) to be the first of many JAK inhibitors to enter the US market for the treatment of atopic dermatitis (AD), the leading data and analytics company notes that developers of these drugs need to find ways to overcome the FDA’s restrictive labelling. Ramla Salad, Pharma Analyst at […]
Read more

Reduced risk of CV morbidity and mortality demonstrated in FIGARO-DKD study

At this year’s European Society of Cardiology (ESC) Congress, positive results were presented from Bayer’s FIGARO-DKD Phase III trial of Kerendia (finerenone), providing insight into the drug’s ability to reduce risk of morbidity and mortality in diabetic kidney disease patients. The positive data from the FIGARO-DKD study will help support the use of finerenone to […]
Read more

Combination therapy approaches may be the most promising method for glioblastoma multiforme patients, says GlobalData

With Bristol Myers Squibb’s (BMS) Phase III CheckMate-498 and CheckMate-143 Opdivo (nivolumab) studies both failing to meet primary or secondary endpoints, the use of single-agent PD-1 blockade for glioblastoma multiforme (GBM) remains unsatisfactory, says GlobalData. The leading data and analytics company notes; considering that multiple immunosuppressive mechanisms and low immunogenic responses are observed in GBM, […]
Read more

Faster approvals likely to make CAR-T landscape competitive in China, says GlobalData

China’s National Medical Products Administration (NMPA) has approved its second chimeric antigen receptor T (CAR-T) cell immunotherapy product JW Therapeutics’ relmacabtagene autoleucel injection (relma-cel) shortly after the approval of its first CAR-T therapy, Gilead & FosunKite’s Yescarta, in June 2021. With several CAR-T therapies in Phase II pipeline in China, particularly dominated by domestic companies, […]
Read more

Amylyx’s ALS drug AMX0035 likely available much sooner than expected, says GlobalData

Following the recent shift in the FDA’s stance on Amylyx Pharmaceuticals’ AMX0035* new drug application (NDA), leading data and analytics company, GlobalData, expects that this drug could be available for amyotrophic lateral sclerosis (ALS) patients much sooner than anticipated. Sarah Elsayed, Neurology Analyst at GlobalData, comments: “As AMX0035 targets a serious neurological condition with huge […]
Read more

Vertex to replace Trikafta as gold standard treatment for cystic fibrosis but other CTFR therapies welcome, says GlobalData

Of the five late-stage pipeline products expected to be licensed in the 7MM* for cystic fibrosis (CF) between 2020 and 2030, four will be CF transmembrane conductance regulator (CFTR) modulators, according to GlobalData. The leading data and analytics company notes that Vertex’s next-generation triple combination, VX-121 + tezacaftor + VX-561 (deutivacaftor), is expected to replace […]
Read more

Delays in availability will impact overall market potential of recently approved COVID-19 vaccines in India, says GlobalData

India currently has six approved COVID-19 vaccines. However, Zydus Cadila’s, Johnson & Johnson’s, and Moderna’s vaccines are not yet available in India. Considering the gigantic vaccination drive in India, any delay in their availability will impact the overall market potential of the recently approved COVID-19 vaccines, says GlobalData, a leading data and analytics company. On […]
Read more

Loss of touch, inconsistent video call technology are key drivers for doctors to opt for face-to-face consultations, says GlobalData

Returning to face-to-face GP appointments is drawing interest from all sectors, as it could be used as another indicator of routine life reverting to prepandemic levels. Indeed, there are diseases that require the sense of touch for proper diagnosis and patient monitoring, which cannot be done via video calls, according to reporting by Reynald Castañeda, […]
Read more

India needs more digital public initiatives on diabetes, obesity, and mental health amid COVID-19 era, says GlobalData

In collaboration with the LaparoObeso center, the Indian state of Maharashtra has recently launched a digital campaign to raise awareness of diabetes and obesity. In addition, the Indian state of Delhi’s premier medical institute, All India Institute of Medical Sciences, Delhi (AIIMS Delhi), has developed mobile apps for patients with chronic mental illness and their […]
Read more
1 … 55 56 57 58 59 … 108